Acadia Pharmaceuticals Inc. saw its stock soar following a crucial court ruling that upheld the validity of a key patent for its drug, Nuplazid. On December 13, 2023, the U.S. District Court for the District of Delaware ruled in favor of Acadia by affirming the '740 composition of matter patent for Nuplazid. This decision bars generic versions until 2030, securing Acadia's competitive edge with this Parkinson's disease medication. The company's stock surged approximately 35% after the announcement, signaling robust investor confidence in the drug's continued exclusivity.
According to Zacks, the favorable court decision significantly enhanced Acadia's stock performance. The stock reached an intraday high of $25.00, with a closing price of $23.85, reflecting a change of $6.25 from the previous close. This increase aligns with investors' optimism about the sustained market presence of Nuplazid, which remains the first FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis.
Alongside the re-affirmed '740 patent, Acadia also holds other critical patents, including a method of use patent for the 10mg tablet that extends to 2037, and formulation patents for the 34mg capsule until 2038. This breadth of patent coverage positions Nuplazid firmly in the market, continuing to contribute significantly to the company's revenue stream. The legal success empowers Acadia with a fortified stance in the pharmaceutical market, reinforcing its financial prospects over the coming years.